ADMA Biologics Inc (ADMA)vsRegeneron Pharmaceuticals Inc (REGN)
ADMA
ADMA Biologics Inc
$8.75
+0.34%
HEALTHCARE · Cap: $2.02B
REGN
Regeneron Pharmaceuticals Inc
$632.90
+2.06%
HEALTHCARE · Cap: $66.35B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 2826% more annual revenue ($14.92B vs $509.86M). ADMA leads profitability with a 32.4% profit margin vs 29.6%. ADMA trades at a lower P/E of 12.8x. REGN earns a higher WallStSmart Score of 64/100 (C+).
ADMA
Hold49
out of 100
Grade: D+
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ADMA.
Margin of Safety
+53.0%
Fair Value
$1346.63
Current Price
$632.90
$713.73 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 42 in profit
Keeps 32 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
15.9% revenue growth
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Earnings declined 52.8%
Operating margin of -123.4%
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ADMA
The strongest argument for ADMA centers on Return on Equity, Profit Margin, Altman Z-Score. Profitability is solid with margins at 32.4% and operating margin at -123.4%. Revenue growth of 15.9% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : ADMA
The primary concerns for ADMA are EPS Growth, Operating Margin.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ADMA carries more volatility with a beta of 0.73 — expect wider price swings.
REGN is growing revenue faster at 19.0% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (64/100 vs 49/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ADMA Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?